The Innovative Medicines Initiative (IMI) grant will support a five-year project coordinated by Fisabio, a not-for-profit scientific and healthcare research body based in Spain. The project will bring together 15 partners, including large pharmaceuticals companies such as Sanofi and GlaxoSmithKline, to develop a sustainable and strong network of those performing brand-specific vaccine effectiveness assessments.
Assessing the efficacy of vaccines is an essential part of healthcare research, and the collaboration and partnership of a range of stakeholders, such as public health institutes, universities, regulatory bodies and vaccine manufacturers, is necessary to build a strong platform for these assessments.
Professor of Primary Care and Clinical Informatics, Simon de Lusignan, who specialises in quality improvement through data collection, said:
This grant develops our work at the cutting edge of vaccine effectiveness studies, increasing the immediacy and reducing the time to generating outcomes from research. This should ultimately mean better vaccines and contribute to improvements in public health.
This project furthers the work already being carried out by the University of Surrey’s Department of Clinical and Experimental Medicine (DECM), headed by Professor de Lusignan. This includes the Surrey Clinical Research Centre which is having a significant impact on the future of vaccine research.